Yves Durocher, J Glycobiol 2016, 4:2(Suppl)
http://dx.doi.org/10.4172/2168-958X.C1.006

Development of a CHO cell culture platform for monoclonal antibody production: from clone generation to pilot-plant scale-up

Yves Durocher
National Research Council Canada, Canada

The National Research Council Canada (NRC) has developed an inducible CHOBRI cell line platform, employing a generic approach for the fast development of monoclonal antibodies (mAbs) or therapeutic proteins production processes.

Starting from CHO pools that can produce gram quantities of mAbs, clones are selected and process conditions are optimized for scale-up to a pilot plant scale production (20-200L).

The final process delivers material for toxicity studies and can seamlessly be transferred to a GMP production facility.

Biography

Yves Durocher is a Research Officer at the National Research Council of Canada since 1995. He obtained his PhD in Biochemistry at the Université de Montréal in 1993. He manages the NRC's Mammalian Cell Culture Section which is composed of 33 scientists involved in protein expression and CHO cell line development for internal projects and external clients. His research activities have been focused on the development the of large-scale transient gene expression (LSTGE) platforms using HEK293 and CHO cells for protein production and on the development of stable CHO pool and clonal cell line platforms for the manufacturing of recombinant therapeutic proteins. He also contributed to ~100 scientific publications in peer-reviewed journals.

Yves.Durocher@cnrc-nrc.gc.ca

Notes: